Rare Diseases >> Abstract Details   Attenuated Host-Range Restricted Dengue Viruses Derived by Site-Directed Mutagenesis of the Conserved 3-Stem and Loop Structure in Genomic RNA for Use as Vaccines Description of Invention: Although flaviviruses cause a great deal of human suffering and economic loss, there is a shortage of effective vaccines. The present invention is directed toward vector stage replication-defective flaviviruses that are replication-defective in mosquito vectors that transmit them to humans. The replication-defective flaviviruses of the present invention demonstrate a limited ability to replicate in the vector organisms that transmit flaviviruses from one host to another. More specifically, the present invention is directed toward the construction and propagation of flaviviruses that possess 3'-noncoding regions altered in such a way as to prevent or severely limit viral reproduction in a vector organism. Not only is the dengue 1 mutant replication defective in mosquitoes, but it is also attenuated and immunogenic in monkeys. Moreover, it protects against challenge, thus it has strong potential as a dengue vaccine. Inventors: Lingling Zeng and Lewis Markoff (CBER/FDA) Patent Status: DHHS Reference No. E-067-1998/0 -- U.S. Patent No. 6,685,948 issued 03 Feb 2004 Portfolios: Infectious Diseases Infectious Diseases -Vaccines-Viral-Non-AIDS (only) Infectious Diseases -Vaccines-Viral Infectious Diseases -Vaccines For Additional Information Please Contact: Peter A. Soukas J.D. NIH Office of Technology Transfer 6011 Executive Blvd, Suite 325 Rockville, MD 20852-3804 Phone: (301) 435-4646 Email: soukasp@mail.nih.gov Fax: (301) 402-0220 Web Ref: 470 Last Updated On: 5/01